Citations

Mayo Clinic

Showing 10 of 108551 citations.

Adapting a Cancer Literacy Measure for Use Among Navajo Women
Yost, Kathleen J. , Bauer, Mark , Buki, Lydia P. , Austin-Garrison, Martha A., Garcia, Linda, Hughes, Christine A. , Patten, Christi A.

Journal of Transcultural Nursing | February 15, 2016 | Volume: 28 | Issue: 3 | Pages: 278-285

10.1177/1043659616628964 | PMID 26879319 Get It

Purpose: The authors designed a community-based participatory research study to develop and test a family-based behavioral intervention to improve cancer literacy and promote mammography among Navajo women. Method: Using data from focus groups and discussions with a community advisory committee, they adapted an existing questionnaire to assess cancer knowledge, barriers to mammography, and cancer beliefs for use among Navajo women. Questions measuring health literacy, numeracy, self-efficacy, cancer communication, and family support were also adapted. Results: The resulting questionnaire was found to have good content validity, and to be culturally and linguistically appropriate for use among Navajo women. Conclusions: It is important to consider culture and not just language when adapting existing measures for use with AI/AN (American Indian/Alaskan Native) populations. English-language versions of existing literacy measures may not be culturally appropriate for AI/AN populations, which could lead to a lack of semantic, technical, idiomatic, and conceptual equivalence, resulting in misinterpretation of study outcomes.
Medicare payment transparency
Jones, Lyell K. , Craft, Karolina, Fritz, Joseph V., Jones, Lyell K

Neurology Clinical Practice | February 15, 2016 | Volume: 6 | Issue: 1 | Pages: 73-80

10.1212/cpj.0000000000000197 | PMID 29443257 Get It

A tardy tongue palsy
O’Gorman, Cullen , Lindell, E. Paul , Klaas, James P. , O'Gorman, Cullen M, Van Gompel, Jamie J, Gompel, Jamie J. Van , O'gorman, Cullen M

Neurology Clinical Practice | February 15, 2016 | Volume: 6 | Issue: 1 | Pages: No page available

10.1212/cpj.0000000000000193 | PMID 29443268 Get It

A Randomized Trial of Induction Therapy (Daunorubicin, Vincristine, Prednisone versus Daunorubicin, Vincristine, Prednisone, Cytarabine and 6-Thioguanine) in Adult Acute Lymphoblastic Leukemia with Long-term Follow-up: An Eastern Cooperative Oncology Group
Wiernik, Peter H. , Cassileth, Peter A., Leong, Traci , Hoagland, H. Clark, Bennett, John M. , Paietta, Elisabeth , Oken, Martin M.

Leukemia & Lymphoma | February 15, 2016 | Volume: 44 | Issue: 9 | Pages: 1515-1521

10.3109/10428190309178773 | PMID 14565653 Get It

Editorial: PPI‐responsive oesophageal eosinophilia and long‐term PPI treatment
Alexander, Jeffrey A. , Katzka, David A.

Alimentary Pharmacology & Therapeutics | February 15, 2016 | Volume: 43 | Issue: 6 | Pages: 744-745

10.1111/apt.13528 | PMID 26876285 Get It

Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors
Moustafa, Sherif, Ho, Thai H. , Shah, Parth , Murphy, Katie , Nelluri, B.K., Lee, Howard , Wilansky, Susan , Mookadam, Farouk , Nelluri, Bhargava K, Ho, Thai

Journal of Clinical Ultrasound | February 15, 2016 | Volume: 44 | Issue: 4 | Pages: 221-230

10.1002/jcu.22333 | PMID 26875513 Get It

ABSTRACTPurposeWe aimed to explore the hypothesis that early subclinical cardiac chamber dysfunction secondary to tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma could be signaled by abnormal cardiac mechanics demonstrated by velocity vector imaging.MethodsEchocardiographic images were acquired from the apical views in 23 metastatic renal cell carcinoma patients. All patients had baseline and at least a 3‐month follow‐up echocardiogram after receiving TKI therapy. Subendocardial borders of all the cardiac chambers were traced to obtain volumetric and deformation indices.ResultsMean age was 67 ± 9 years with 92% men. The right ventricle peak systolic global longitudinal strain (GLɛ) and strain rate were significantly lower after TKIs (−23.49 ± 5.1 versus −19.81 ± 5.5, p = 0.002 and −1.52 ± 0.52 versus −1.24 ± 0.35 p = 0.02, respectively). LV GLɛ was not statistically different. Volumetric and deformation indices showed a minimal decrease of the right atrium reservoir and conduit functions, and no significant changes of left atrial function.ConclusionsThe right heart exhibited greater strain changes than the left heart after TKI treatment. The implications of these findings and their potential significance warrant further work. © 2016 Wiley Periodicals, Inc. J Clin Ultrasound 44:221–230, 2016
Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease
Loftus, Edward V. , Moon, Won Kyu , Loftus, Edward V

Alimentary Pharmacology & Therapeutics | February 15, 2016 | Volume: 43 | Issue: 8 | Pages: 863-883

10.1111/apt.13559 | PMID 26876431 Get It

SummaryBackgroundAzathioprine and mercaptopurine have a pivotal role in the treatment of inflammatory bowel disease (IBD). However, because of their complex metabolism and potential toxicities, optimal use of biomarkers to predict adverse effects and therapeutic response is paramount.AimTo provide a comprehensive review focused on pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy inIBD.MethodsA literature search up to July 2015 was performed in PubMed using a combination of relevant MeSHterms.ResultsPre‐treatment thiopurine S‐methyltransferase typing plus measurement of 6‐tioguanine nucleotides and 6‐methylmercaptopurine ribonucleotides levels during treatment have emerged with key roles in facilitating safe and effective thiopurine therapy. Optimal use of these tools has been shown to reduce the risk of adverse effects by 3‐7%, and to improve efficacy by 15–30%. For the introduction of aldehyde oxidase (AOX) into clinical practice, the association betweenAOXactivity andAZAdose requirements should be positively confirmed. Inosine triphosphatase assessment associated with adverse effects also shows promise. Nucleoside diphosphate‐linked moiety X‐type motif 15 variants have been shown to predict myelotoxicity on thiopurines in East Asian patients. However, the impact of assessments of xanthine oxidase, glutathione S‐transferase, hypoxanthine guanine phosphoribosyltransferase and inosine monophosphate dehydrogenase appears too low to favour incorporation into clinical practice.ConclusionsMeasurement of thiopurine‐related enzymes and metabolites reduces the risk of adverse effects and improves efficacy, and should be considered part of standard management. However, this approach will not predict or avoid all adverse effects, and careful clinical and laboratory monitoring of patients receiving thiopurines remains essential.
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention
Velders, Matthijs A., Abtan, Jérémie , Ardissino, Diego , Harrington, Robert A. , Hellkamp, Anne S., Himmelmänn, Anders, Katus, Hugo A. , Meier, Bernhard , Schulte, Phillip J. , Storey, Robert F. , Wallentin, Lars , Steg, Philippe Gabríel , Angiolillo, Dominick J. , Husted, Steen , James, Stefan Karl , Storey, Robert F , Steg, P Gabriel

Heart | February 14, 2016 | Volume: 102 | Issue: 8 | Pages: 617-625

10.1136/heartjnl-2015-308963 | PMID 26848185 Get It

Objective The effects of ticagrelor in the subpopulation of patients with ST-elevation myocardial infarction (STEMI) were consistent with those observed in the overall Platelet Inhibition and Patient Outcomes (PLATO) study. However, this subgroup included patients initially or ultimately treated conservatively. The aim of this study is to compare treatment using ticagrelor with treatment using clopidogrel in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Methods This post-hoc subgroup analysis compared ticagrelor with clopidogrel in 4949 PLATO patients with STEMI that were treated with primary PCI within 12 h of admission. The primary endpoint was cardiovascular death, myocardial infarction or stroke. The safety endpoint consisted of any major bleeding. Secondary endpoints included stent thrombosis. The analysis was not adequately powered to establish significance of any treatment effects. Results During a median of 286 days, the primary endpoint occurred in 7.9% of ticagrelor-treated patients versus 8.6% of clopidogrel-treated patients (HR 0.91, 95% CI 0.75 to 1.12, p=0.38). Major bleeding occurred in 6.7% in ticagrelor-treated patients versus 6.8% of clopidogrel-treated patients (HR 0.97, 95% CI 0.77 to 1.22, p=0.79). No interactions were observed for the treatment effect of ticagrelor versus clopidogrel on the primary efficacy (p=0.40) and primary safety endpoints (p=0.15) as compared with the full PLATO population. Treatment with ticagrelor versus clopidogrel reduced the occurrence of definite stent thrombosis (HR 0.58, 95% CI 0.37 to 0.89, p=0.013). Conclusions In the subset of patients with STEMI treated with primary PCI, ticagrelor compared with clopidogrel was safe, and efficacy outcomes were consistent with the overall PLATO trial. Trial registration number NCT00391872; Results.
Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation
Hijazi, Ziad , Aulin, Julia , Andersson, Ulrika , Alexander, John H. , Granger, Christopher B. , Hanna, Michael G. , Horowitz, John D. , Siegbahn, Agneta , Wallentin, Lars , Gersh, Bernard J. , Hylek, Elaine M. , Lópes, Renato D. , Granger, Christopher B

Heart | February 14, 2016 | Volume: 102 | Issue: 7 | Pages: 508-517

10.1136/heartjnl-2015-308887 | PMID 26839066 Get It

Objective Atrial fibrillation (AF) is a risk factor for stroke and mortality and the prothrombotic state has been linked to inflammation. In this study we evaluated the relationship between inflammatory biomarkers at baseline and future risk of cardiovascular events in the Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Methods The ARISTOTLE trial randomised 18 201 patients with AF to apixaban or warfarin. Interleukin 6 (IL-6) and C reactive protein (CRP) were analysed in plasma obtained at randomisation from 14 954 participants, and median follow-up was 1.9 years. Association between quartile groups of IL-6 and CRP and outcomes were analysed by Cox regression adjusted for clinical risk factors and other cardiovascular biomarkers (NT-proBNP, troponin, GDF-15, cystatin C). Results The IL-6 median level was 2.3 ng/L (IQR 1.5–3.9), median CRP level was 2.2 mg/L (1.0–4.8). IL-6 and CRP were significantly associated with all-cause mortality independent of clinical risk factors and other biomarkers (HR (95% CI) 1.93 (1.57 to 2.37) and 1.49 (1.24 to 1.79), respectively, Q4 vs Q1). IL-6 was associated with myocardial infarction, cardiovascular mortality, and major bleeding beyond clinical risk factors but not in the presence of cardiovascular biomarkers (NT-proBNP, troponin, GDF-15, cystatin C). Neither inflammatory biomarker was associated with stroke/systemic embolism. Risk prediction for stroke, death and major bleeding was not improved by IL-6 or CRP when added to clinical risk factors and the other cardiovascular biomarkers (NT-proBNP, troponin, GDF-15, cystatin C). Conclusions In patients with AF on anticoagulation, after accounting for clinical risk factors and other biomarkers, biomarkers of inflammation were significantly associated with an increased risk of mortality. However, there were no associations with the risk of stroke or major bleeding. Trial registration number ClinicalTrials.gov identifier: NCT00412984 post-results.
Spontaneous coronary artery dissection and its association with heritable connective tissue disorders
Negrotto, Sara , Kirmani, Salman , Deyle, David R. , Gulati, Rajiv , Olson, Timothy M. , Negrotto, Sara M, Tweet, Marysia S. , Henkin, Stanislav , Hayes, Sharonne N. , Olson, Timothy M

Heart | February 14, 2016 | Volume: 102 | Issue: 11 | Pages: 876-881

10.1136/heartjnl-2015-308645 | PMID 26864667 Get It

Objective Spontaneous coronary artery dissection (SCAD) is an under-recognised but important cause of myocardial infarction and sudden cardiac death. We sought to determine the role of medical and molecular genetic screening for connective tissue disorders in patients with SCAD. Methods We performed a single-centre retrospective descriptive analysis of patients with spontaneous coronary artery disease who had undergone medical genetics evaluation 1984–2014 (n=116). The presence or absence of traits suggestive of heritable connective tissue disease was extracted. Genetic testing for connective tissue disorders and/or aortopathies, if performed, is also reported. Results Of the 116 patients (mean age 44.2 years, 94.8% women and 41.4% with non-coronary fibromuscular dysplasia (FMD)), 59 patients underwent genetic testing, of whom 3 (5.1%) received a diagnosis of connective tissue disorder: a 50-year-old man with Marfan syndrome; a 43-year-old woman with vascular Ehlers–Danlos syndrome and FMD; and a 45-year-old woman with vascular Ehlers–Danlos syndrome. An additional 12 patients (20.3%) had variants of unknown significance, none of which was thought to be a definite disease-causing mutation based on in silico analyses. Conclusions Only a minority of patients with SCAD who undergo genetic evaluation have a likely pathogenic mutation identified on gene panel testing. Even fewer exhibit clinical features of connective tissue disorder. These findings underscore the need for further studies to elucidate the molecular mechanisms of SCAD.